Article

Drug–drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS- 115 in patients with solid tumors

2025-10-06

Abstract excerpt

<title>Abstract</title> <p> <bold>Purpose</bold> TAS-115 is an oral multi-kinase inhibitor currently under development for the treatment of osteosarcoma and chronic fibrosing interstitial lung diseases with a progressive phenotype. In this study, we evaluated the effect of multiple administrations of TAS-115 on the pharmacokinetic (PK) changes in CYP2C8, CYP2C9, and CYP3A4 substrates, as well as its anti-tumor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 22e7f8dd-e72b-5430-9b06-0c64458053ea
DOI: 10.21203/rs.3.rs-7677215/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Drug–drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS- 115 in patients with solid tumorsDOI 10.21203/rs.3.rs-7677215/v1Read

Comprehensive statistical analysis of the pharmacokinetics, safety and clinical benefit rate of MitoTam in a single-center phase I/Ib trial in patients with metastatic solid tumorsSemantic proximity Read

Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.Semantic proximity Read

Highlights from the latest articles in pharmacogenomics of irinotecan/cisplatin toxicity.Semantic proximity Read

[A review: drug-drug interactions of epithelial growth factor receptor-tyrosine kinase inhibitors].Semantic proximity Read

OATP1B1 plays an important role in the transport and treatment efficacy of sorafenib in hepatocellular carcinomaSemantic proximity Read

Optimizing Cardiovascular Treatment in Non-Small Cell Lung Cancer: A Comprehensive Computational Approach for Assessment of Drug-Drug Interactions Between Tyrosine Kinase Inhibitors and Cardiovascular DrugsSemantic proximity Read

Optimizing Cardiovascular Treatment in Non-Small Cell Lung Cancer: A Comprehensive Computational Approach for Assessment of Drug-Drug Interactions between Tyrosine Kinase Inhibitors and Cardiovascular DrugsSemantic proximity Read

Regorafenib in Bone Sarcoma: A Systematic Review and Meta-Analysis of Its Effectiveness and Safety in Cancer TreatmentSemantic proximity Read

Contributing factors on metabolic mechanism-based CYP3A4-activated/deactivated anticancer drugs: implications for individualizing chemotherapySemantic proximity Read

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.Semantic proximity Read

Drug-Drug Interaction Potential of SH-1028, a Third-generation EGFR-TKI: In Vitro and Clinical TrialsSemantic proximity Read

Safety, Pharmacokinetics, and Preliminary Efficacy of Talazoparib in Japanese Patients With Advanced Solid Tumors: Phase 1 StudySemantic proximity Read